Company profile: Metavention
1.1 - Company Overview
Company description
- Provider of minimally invasive radio frequency denervation therapies for high blood pressure and metabolic diseases via the iRF Denervation System, which disrupts overactive sympathetic nerves. Offers clinical studies including DeLIVER U.S. (hepatic denervation for type 2 diabetes), DeLIVER NZ (renal/hepatic denervation for hypertension), and MODUS Australia (hepatic, renal, or multi-organ denervation).
Products and services
- IRF Denervation System: A minimally invasive system using radio frequency energy to disrupt overactive sympathetic nerves linked to high blood pressure and metabolic diseases through targeted denervation
- MODUS Australia Study: A multi-organ study evaluating safety and performance of hepatic, renal, or combined denervation for treating type 2 diabetes and high blood pressure
- DeLIVER U.S. Study: A hepatic denervation study evaluating the safety and performance of treating type 2 diabetes using the iRF Denervation System
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Metavention
Intuity Medical
HQ: United States
Website
- Description: Provider of blood glucose monitoring systems for diabetes management, featuring the POGO Automatic Monitor that automatically lances, collects blood, and provides results with a single press using 10-test cartridges that integrate lancets and test strips, and the Patterns app to sync, track, visualize trends, share readings, send emergency notifications, and integrate with other health apps.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Intuity Medical company profile →
Poxel
HQ: France
Website
- Description: Provider of biopharmaceutical products for metabolic diseases, focusing on type 2 diabetes and NASH. Portfolio includes TWYMEEG (Imeglimin), approved in Japan for type 2 diabetes, targeting mitochondrial dysfunction; PXL065, a deuterium-stabilized R-pioglitazone for NASH with Phase 2 primary endpoint met; and PXL770, a direct AMPK activator for rare diseases including NASH and ALD.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Poxel company profile →
Intarcia
HQ: United States
Website
- Description: Provider of long-term therapies for chronic diseases, offering the MEDICITM Drug Delivery System for twice-yearly subcutaneous osmotic implants, ITCA 650 (twice-yearly exenatide implant) for type 2 diabetes, and an Ionic Liquid Platform converting injectable biologics and peptides into oral therapies; pipeline includes i2o-105s (long-acting GLP-1 receptor agonist), i2o-107 (long-acting amylin), and i2o-110 (dual agonist) for type 2 diabetes, obesity, and NASH.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Intarcia company profile →
Diasome
HQ: United States
Website
- Description: Provider of insulin-based, liver-targeted diabetes therapeutics utilizing Hepatocyte Directed Vesicles (HDV) to enhance insulin delivery and reduce hypoglycemia risk. The company conducts multiple Phase 2 studies, including OPTI-2 and ISLE-1 Phase 2b trials, the Good to Great study, and an insulin pump crossover study, evaluating HDV added to rapid-acting insulin in patients with Type 1 diabetes.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Diasome company profile →
Protomer
HQ: United States
Website
- Description: Provider of pre-clinical biotechnology R&D focused on metabolic diseases, developing glucose-responsive insulin receptor agonist therapeutics and the Molecular Evolution of Peptide Sensors (MEPS) platform for creating therapeutic peptides and proteins with tunable, small-molecule-controlled activity.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Protomer company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Metavention
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Metavention
2.2 - Growth funds investing in similar companies to Metavention
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Metavention
4.2 - Public trading comparable groups for Metavention
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →